clinical trial · NCT06813911
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)PelacarsenPlaceboInclisiran
brief summary
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).
started
Apr 30, 2025
primary completion
Feb 3, 2028
completion
Feb 29, 2028
last updated
Jun 17, 2026
detailed description
This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study followed by an open-label treatment period.
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol